EZH2 Inhibitor Selective Binding to Mutant Substrate Pocket
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for follicular lymphoma and diffuse large B-cell lymphoma, such as the R-CHOP regimen, are not satisfactory, and there is a need for novel therapies based on genetic profiles, particularly for targeting aberrant EZH2 activity associated with cancer.
Innovation Solution
Administering a therapeutically effective amount of an EZH2 inhibitor to subjects with mutant EZH2 mutations in the substrate pocket domain, which are more responsive to the inhibitor than those with wild-type EZH2, to inhibit histone H3-K27 methylation and treat cancer or precancerous conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments such as the R-CHOP regimen are used for follicular lymphoma and diffuse large B-cell lymphoma, then treatment coverage is provided, but treatment effectiveness is insufficient
Solution Approach 1:
The patent applies local quality by developing an EZH2 inhibitor that specifically targets the substrate pocket domain of mutant EZH2 proteins. The inhibitor is designed to bind selectively to mutant forms (such as Y641C, Y641S, Y641N, Y641F, A677G, A687V) while sparing wild-type EZH2, thereby providing localized therapeutic action at the molecular level. This selective inhibition addresses the inadequacy of non-specific chemotherapy by focusing the therapeutic effect precisely on the aberrant enzymatic activity driving lymphomagenesis.
Solution Approach 2:
The patent employs parameter changes by exploiting differences in the biochemical parameters of mutant versus wild-type EZH2. The substrate pocket domain mutations alter the enzyme's substrate binding affinity and catalytic efficiency, and the inhibitor is designed to capitalize on these parameter changes. By measuring H3-K27me2 and H3-K27me3 levels as biomarkers, the patent establishes quantitative parameters to identify patients whose tumors exhibit the characteristic epigenetic profile (reduced H3-K27me2, normal or elevated H3-K27me3) that predicts responsiveness to EZH2 inhibition.
2Productivity
If EZH2 inhibitors are used to target mutant EZH2 activity, then cancer cell proliferation is reduced, but selective targeting of mutant versus wild-type EZH2 is required
Solution Approach 1:
The inhibitor is designed with local quality by focusing its binding specificity on the substrate pocket domain, which is the region affected by lymphoma-associated mutations. The molecular structure of the inhibitor (such as BIX-01294, GSK126, or Tazemetostat) is optimized to form hydrogen bonds and hydrophobic interactions specifically with the mutant substrate pocket residues, creating a localized binding interface that discriminates between mutant and wild-type EZH2 based on subtle structural differences in the substrate pocket.
Solution Approach 2:
The patent applies inversion by reversing the conventional approach: instead of designing an inhibitor that binds to the catalytic SET domain (which would inhibit both wild-type and mutant EZH2), the inhibitor is designed to bind to the substrate pocket domain. This inverted binding strategy exploits the fact that substrate pocket mutations create a unique binding environment that favors inhibitor binding to mutant forms, thereby inverting the selectivity paradigm from catalytic site inhibition to substrate binding site inhibition.
3Reliability
If H3-K27 methylation is inhibited to treat cancer, then gene expression patterns are restored, but epigenetic changes must be maintained without affecting DNA sequence
Solution Approach 1:
The patent applies preliminary action by using EZH2 inhibition to prevent the accumulation of repressive H3-K27me3 marks before they can permanently silence tumor suppressor genes. By inhibiting EZH2 activity early in the disease process or in newly diagnosed patients, the treatment prevents the establishment of stable epigenetic silencing. The preliminary restoration of gene expression patterns occurs before irreversible epigenetic remodeling takes place, maximizing the therapeutic window for reversing the epigenetic landscape.
Solution Approach 2:
The patent implements feedback by measuring the levels of H3-K27me2 and H3-K27me3 as biomarkers to monitor the epigenetic response to EZH2 inhibition. Patients with reduced H3-K27me2 and normal or elevated H3-K27me3 levels are identified as having the characteristic feedback pattern indicating EZH2 dysregulation. This feedback information is used to select patients most likely to benefit from treatment and to monitor treatment response, ensuring that epigenetic modifications are being appropriately reversed without causing genomic instability.
Data Source
AI summary
The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.